406 filings
424B3
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Prospectus supplement
4:23pm
8-K
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Entry into a Material Definitive Agreement
7:46am
EFFECT
ZVRA
Zevra Therapeutics Inc
9 Apr 24
Notice of effectiveness
12:15am
S-3/A
ZVRA
Zevra Therapeutics Inc
Shelf registration (amended)
5 Apr 24
7:39pm
DEFA14A
ZVRA
Zevra Therapeutics Inc
3 Apr 24
Additional proxy soliciting materials
4:17pm
8-K
fatt9c7q
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K
rzgztj2gwshaexf
26 Mar 24
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
8:28pm
8-K
qza1414
5 Mar 24
Regulation FD Disclosure
7:34am
8-K
fqwx2r0aphybap ydkqv
4 Mar 24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:24am
8-K
q6c7tvhluerflaan5y3v
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K/A
6339u6cw
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
cp8cbh 3ug2xztqf0
23 Jan 24
Departure of Directors or Certain Officers
7:37am
8-K
c6jxk d9o
8 Jan 24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:03am
8-K
lcduvvwi3wt 8ub
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
kueu6gy2
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
hk5yn33v
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am